Upcoming Opportunities in CINV Existing and Pipeline Drugs Market: Future Trend and Analysis of Key Segments and Forecast 2022-2031

CINV Existing and Pipeline Drugs Market Outlook 2031
The global CINV existing and pipeline drugs market was valued at US$ 1.9 Bn in 2021

It is estimated to grow at a CAGR of 5.8% from 2022 to 2031

The global CINV existing and pipeline drugs market is expected to surpass value of US$ 3.2 Bn by the end of 2031

Report Overview:https://www.transparencymarketresearch.com/cinv-market.html

Overview of Global CINV Existing and Pipeline Drugs Market
Chemotherapy-induced nausea and vomiting (CINV) refers to nausea and vomiting associated with cancer chemotherapy. CINV is one of the most common side effects experienced by cancer patients undergoing chemotherapy. Presently, several drugs are available to manage CINV; however, side effects continue to be a key concern for patients and oncologists associated with chemotherapy. Companies such as Helsinn Holding S.A., Heron Therapeutics, Inc., and Tesaro, Inc. are striving to develop new and more efficacious therapeutic solutions to treat CINV.

Increase in Incidence Rate of Various Types of Cancer
The world is witnessing a continuous increase in the incidence rate of various types of cancer, which results in rise in the number of patients undergoing chemotherapy. According to estimates from the World Health Organization (WHO) in 2019, cancer is the first or second leading cause of death before the age of 70 years in 112 of 183 countries, and ranks third or fourth in a further 23 countries. These facts indicate that increase in cases of various types of cancer is likely to induce oncologists to prescribe chemotherapy to their patients for the effective treatment of cancer, thereby driving the CINV existing and pipeline drugs market.

Generally, 25% to 30% patients with cancer receive chemotherapy as a treatment option, and 70% to 80% of these patients undergoing chemotherapy exhibit nausea and vomiting as major symptoms.

Request Sample:https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=776

Companies Undertaking R&D Activities to Develop Advanced Drugs
Significant rise in cancer research and development efforts and increase in attention on the development of novel therapies are expected to drive the global CINV existing and pipeline drugs market over the next few years. Additionally, the introduction of new pharmaceuticals and the rapid growth of the healthcare industry are expected to propel the market in the near future. However, consumers' lack of information regarding the availability of innovative and effective pharmaceuticals and treatments is projected to impact the growth of the market in the next years.

SUSTOL (APF-530) Segment to Dominate Global Market
SUSTOL (APF-530) was launched in 2015. The approval of SUSTOL drugs is likely to drive the global market during the forecast period. Increase in the number of patients undergoing chemotherapy is expected to contribute to the growth of the global CINV existing and pipeline drugs market. Various sources indicate that 70% to 80% cancer patients on chemotherapy exhibit nausea and vomiting as major side effects.

Rolapitant to Witness Demand Due to Ability to Suppress Vomiting
Rolapitant was approved in 2015. Since then, the demand for the drug has increased among various countries. Pipeline drugs have shown better efficacy than existing drugs during the clinical study. Rolapitant is used with other drugs to delay nausea and vomiting caused by cancer drug treatment (chemotherapy). It acts by suppressing one of the body's natural chemicals (substance P/neurokinin 1) that produces vomiting. Therefore, the launch of these more efficacious drugs is likely to encourage physicians to prescribe these new drugs over existing drugs

Enquiry Before Buying:https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=776

Regional Outlook of Global CINV Existing and Pipeline Drugs Market
The global CINV existing and pipeline drugs market has been segmented into North America, Europe, Asia Pacific Latin America, and Middle East & Africa. North America was the largest market for CINV drugs in 2021, accounting for over 45% share. The region is expected to retain its leadership position during the forecast period. The market in North America is likely to expand at a CAGR of over 7% from 2022 to 2031.

Europe was the second largest market for CINV drugs in 2021. The launch of CINV pipeline drugs in Europe is projected to be a year later than in North America, given the delays on the past launches of CINV drugs such as Aloxi and Emend.

The CINV existing and pipeline drugs market in Asia Pacific is driven by increase in penetration of western companies and rise in the number of cancer patients. Generic manufacturers in countries in Asia Pacific and emerging regions compete with the branded CINV drug manufacturers. The demand for generic versions of expired branded drugs is high in the region due to low purchasing power of the people. Strong economic growth in countries such as India and China and improving healthcare infrastructure are anticipated to drive the CINV existing and pipeline drugs market in Asia Pacific.

Analysis of Key Players in Global CINV Existing and Pipeline Drugs Market
Key players operating in the global CINV existing and pipeline drugs market include GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc., and Tesaro, Inc. Each of these players has been profiled in the global CINV existing and pipeline drugs market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments.

Request Customization:https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=776

More Trending Reports of Transparency Market Research:

Chronic Pelvic Pain Treatment Market: https://www.transparencymarketresearch.com/chronic-pelvic-pain-treatment-market.html

Controlled Substance Market: https://www.transparencymarketresearch.com/us-controlled-substance-market.html

Tree Nut Allergy Market: https://www.transparencymarketresearch.com/us-tree-nut-allergy-market.html

Cannabinoids Market: https://www.transparencymarketresearch.com/cannabinoids-market.html

Albumin Market: https://www.transparencymarketresearch.com/global-albumin-market.html

Microbiology Culture Market: https://www.transparencymarketresearch.com/us-microbiology-culture-market.html

Vascular Graft Market: https://www.transparencymarketresearch.com/vascular-graft-market.html

Nasal Dressings Market: https://www.transparencymarketresearch.com/nasal-dressings-market.html

Contact
Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com

About Transparency Market Research

Transparency Market Research registered at Wilmington, Delaware, United States, is a global market research company providing custom research and consulting services. TMR provides in-depth insights into factors governing demand in the market. It divulges opportunities across various segments based on Source, Application, Sales Channel, and End-Use that will favor growth in the market over the next 9 years.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

This release was published on openPR.